Rally

Rallybio is a clinical-stage biotechnology company focused on developing life-altering therapies for patients with severe and rare diseases. The company's lead candidate, RLYB001, is a monoclonal antibody designed to prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a potentially devastating rare disease. Rallybio is also advancing a portfolio of complement inhibitors, including RLYB002, targeting diseases like Paroxysmal Nocturnal Hemoglobinuria. Led by a management team with extensive experience in rare disease drug development from Alexion, the company aims to address significant unmet medical needs through a diversified pipeline of biologics and small molecules.